Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 5/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16845096 | 0.95 | ADRA2C (0.57) | ADRA2CADRA1AKMT2AL3MBTL1L3MBTL3 | |
| Trifluoroacetic Acid SCHEMBL18185582 | 0.89 | ADRA1A (0.49) | ADRA2CADRA1A | |
| SCHEMBL16845178 | 0.84 | ADRA1A (0.53) | ADRA2CADRA1A | |
| SCHEMBL29787244 | 0.77 | ADRA2C (0.84) | ADRA2CKMT2AMEN1ALDH1A1 | |
| SCHEMBL25426308 | 0.77 | ADRA2C (0.84) | ADRA2CKMT2AMEN1ALDH1A1 | |
| SCHEMBL24183555 | 0.77 | ADRA2C (0.84) | ADRA2CKMT2AMEN1ALDH1A1 | |
| SCHEMBL30398366 | 0.77 | ADRA2C (0.84) | ADRA2CKMT2AMEN1ALDH1A1 | |
| SCHEMBL25426753 | 0.77 | ADRA2C (0.84) | ADRA2CKMT2AMEN1ALDH1A1 | |
| SCHEMBL29787322 | 0.77 | ADRA2C (0.84) | ADRA2CKMT2AMEN1ALDH1A1 | |
| SCHEMBL30359158 | 0.77 | ADRA2C (0.84) | ADRA2CKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | TNNI3, TNNC1, FABP3 | ADRA2C 678/4885ADRA1A 1241/4885KMT2A 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.